ALLO Allogene Therapeutics Inc

Price (delayed)

$12.28

Market cap

$1.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$1.74B

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
ALLO's quick ratio is up by 28% since the previous quarter but it is down by 3.6% year-on-year
ALLO's revenue has dropped by 99% since the previous quarter and by 99% year-on-year
The gross profit has dropped by 99% since the previous quarter and by 99% year-on-year

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
143.6M
Market cap
$1.76B
Enterprise value
$1.74B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.05
Price to sales (P/S)
8,467.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,476.3
Earnings
Revenue
$205,000
EBIT
-$303.84M
EBITDA
-$291.61M
Free cash flow
-$220.61M
Per share
EPS
-$2.2
Free cash flow per share
-$1.56
Book value per share
$5.99
Revenue per share
$0
TBVPS
$6.82
Balance sheet
Total assets
$964.63M
Total liabilities
$109.4M
Debt
$69.04M
Equity
$855.23M
Working capital
$432.87M
Liquidity
Debt to equity
0.08
Current ratio
12.74
Quick ratio
12.46
Net debt/EBITDA
0.09
Margins
EBITDA margin
-142,249.8%
Gross margin
100%
Net margin
-148,214.6%
Operating margin
-147,602%
Efficiency
Return on assets
-28.9%
Return on equity
-32.3%
Return on invested capital
-34.2%
Return on capital employed
-32.8%
Return on sales
-148,214.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
0.74%
1 week
12.04%
1 month
67.3%
1 year
-49.17%
YTD
-17.69%
QTD
34.8%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$205,000
Gross profit
$205,000
Operating income
-$302.58M
Net income
-$303.84M
Gross margin
100%
Net margin
-148,214.6%
ALLO's revenue has dropped by 99% since the previous quarter and by 99% year-on-year
The gross profit has dropped by 99% since the previous quarter and by 99% year-on-year
The net income has decreased by 33% YoY and by 18% QoQ
ALLO's operating income is down by 29% year-on-year and by 18% since the previous quarter

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
2.05
P/S
8,467.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,476.3
The EPS has contracted by 20% YoY and by 16% from the previous quarter
ALLO's price to book (P/B) is 27% less than its last 4 quarters average of 2.8
Allogene Therapeutics's equity has decreased by 20% YoY and by 7% QoQ
ALLO's revenue has dropped by 99% since the previous quarter and by 99% year-on-year

Efficiency

How efficient is Allogene Therapeutics business performance
The return on equity has dropped by 57% year-on-year and by 25% since the previous quarter
The return on assets has dropped by 55% year-on-year and by 25% since the previous quarter
ALLO's return on invested capital is down by 43% year-on-year and by 19% since the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
ALLO's current ratio is up by 30% from the previous quarter but it is down by 2.5% YoY
ALLO's quick ratio is up by 28% since the previous quarter but it is down by 3.6% year-on-year
Allogene Therapeutics's debt is 92% less than its equity
The company's debt to equity has surged by 60% YoY
Allogene Therapeutics's debt has increased by 34% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.